Skip to Content
Søk Menu
Velkommen til lungekreft

Få de nyeste artiklene og MEDtalks om lungekreft

Siste nytt om lungekreft

A New Treatment Breakthrough for EGFR-mutated Lung Cancer

  • / Seppo W. Langer
Bjørn Henning Grønberg

Flere positive overlevelsesdata for ikke-småcellet lungekreft presentert i 2025

/ Bjørn Henning Grønberg
LungekreftOnkologisk Forum 2025 Play the Video
Matilde Grupe Frost

Gender-Based Outcomes in Advanced NSCLC

/ Matilde Grupe Frost
LungekreftNSCLC Play the Video
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungekreft Play the Video

Lung Cancer Highlights

Norwegian and Nordic Lung Cancer Insights – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Lung Cancer Insights: What’s New in the Field – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Lung Cancer Insights: What’s New in the Field

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft
Pasi Jänne

New Class of Medicines Emerge as Potential Therapies in MTAP-Deleted NSCLC

/ Pasi Jänne
LungekreftNSCLCWCLC25 Play the Video

MEDtalks

Michael Stenger

WCLC 2025: Lung Cancer Screening and Early Results from the Danish PLUS Trial

/ Michael Stenger
LungekreftWCLC25 Play the Video
Maria Silvoniemi

Clinical Dilemmas in the Management of NSCLC Without Driver Mutations

/ Maria Silvoniemi
LungekreftNSCLC Play the Video
Bjørn H Grønberg

Perioperativ behandling ved ikke-småcellet lungekreft

/ Bjørn Henning Grønberg
Lungekreft Play the Video
Luis Paz-Ares

ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

/ Luis Paz-Ares
ASCO25Lungekreft Play the Video
Odd Terje Brustugun

Perspektiver på behandlingsvalg ved NSCLC uten drivermutasjoner

/ Odd Terje Brustugun
Lungekreft Play the Video
Bjørn H Grønberg

Kombinasjonsbehandling for EGFR-mutert lungekreft viser økt overlevelse

/ Bjørn Henning Grønberg
Lungekreft Play the Video
Load more

Artikler

Jens Benn’s Encounter with Heine Was Pivotal in His Choice of Lung Oncology

/ Jens Benn Sørensen / Amanda Feldballe Bernholm
Lungekreft

New Data Support Osimertinib as a Backbone Treatment for EGFRm Advanced NSCLC

/ Jan Andreasen
LungekreftNSCLCWCLC25

Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: PALOMA-2 Update

/ Jan Andreasen
LungekreftNSCLCWCLC25

First-Line NSCLC Without Driver Mutations: Practice, Gaps, and Costs

/ Ronny Öhman / Jan Andreasen
LungekreftNSCLC

Lazertinib + Amivantamab: A New Chemotherapy-Free Option for EGFR-Mutated Advanced NSCLC

/ Antonio Passaro / Jan Andreasen
Lungekreft

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungekreft

Back to top